Navigation Links
Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting

SAN FRANCISCO, Nov. 11 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, today announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products for different spine therapy areas at the North American Spine Society (NASS) 2009 Annual Meeting, taking place November 10th through 14th in San Francisco, California. To date MagniFuse has been used in 40 spinal surgeries in the United States.

"Our strategy is to utilize our platform technologies to develop procedure-specific products to address critical unmet surgical needs and we are very excited to be highlighting our MagniFuse platform at NASS," said Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer. "By utilizing our MagniFuse product line in posterior cervical, posterolateral and spinal deformity procedures, Osteotech is targeting a significant segment of the spinal therapy area. Feedback from surgeons that have used MagniFuse to date indicates the differentiated characteristics and capabilities supported by our MagniFuse technology have been well received, and we believe we are strongly positioned to become a market leader."

MagniFuse is a patented, next-generation technology platform that supports a family of high-performance, procedure-specific products that provide for simplified, precision grafting when injury or disease creates a need for bone fusion or new bone growth.

"In addition, we are also looking forward to showcasing our leading-edge FacetLinx(TM) Fusion Technology and Plexur M(TM) Innovative Grafting at NASS," continued Mr. Owusu-Akyaw. "Similar to MagniFuse, these products have received very positive responses in the market and we believe they will both play an important role in our future success. Our goal at Osteotech is to continue to commercialize proprietary biologics designed to address the unmet needs of the surgeon community and we believe these introductions illustrate our ability to successfully execute this strategy. We are pleased to share them directly with the physician community through NASS this week."

New MagniFuse Technology Products

Osteotech is showcasing three procedure-specific forms for three different spine therapy areas in the Company's booth at NASS: PC (posterior cervical), SD (spinal deformity) and PL (posterolateral).

  • MagniFuse PC (posterior cervical) - Posterior cervical fusion is a surgical procedure to stop motion between two or more vertebrae that may be causing neck pain or damage to the nerves that extend into the upper extremities.
  • MagniFuse SD (spinal deformity) - Spinal deformities, or curves in the spine, often develop during growth in adolescence or as a result of aging. MagniFuse will be utilized in the treatment of scoliosis, a frontal spinal deformity where the normal straight alignment of the spine from the front is affected by a curve to the left or right.
  • MagniFuse PL (posterolateral) - Posterolateral fusion involves placing bone graft in the posterolateral portion of the spine. This procedure may be recommended as a surgical treatment option for patients with a condition causing spinal instability, such as degenerative disc disease, spondylolisthesis or spinal stenosis, which has not responded to conservative treatment measures (rest, physical therapy or medication).

MagniFuse Technology Platform

Osteotech's MagniFuse technology platform and related products offer unique, differentiating features compared with other bone grafts on the market:

  • As a result of Osteotech's proprietary manufacturing and processing technology, MagniFuse utilizes a highly active biologic material, derived from an allograft source material containing a higher concentration of multiple natural human growth factors.
  • This formulation is delivered in a unique, resorbable, mesh bag delivery-containment system that is sized specifically for the procedure application, eliminating the graft migration-related issues facing competitive products. It is also radiopaque, enabling surgeons to confirm both intra- and post-operation placement of the graft.
  • The combination of MagniFuse's formulation and delivery system provides an optimized scaffold comprised of 100% bone material that produces targeted bone formation, as evidenced by our clinical data to date.
  • Osteotech worked with a team of recognized spine surgeons and used their feedback in the development of the specific procedural forms within the MagniFuse line of products based on sizing and surgical techniques used in spinal surgeries.

Plexur M Innovative Grafting

Plexur M, a biocomposite combination of cortical bone fibers and resorbable polymers, may be used in a variety of orthopedic procedures as a bone void filler. Developed utilizing the Company's proprietary Plexur® technology, Plexur M offers a number of unique characteristics for orthopedic surgeons:

  • Plexur M is pliable and moldable when heated, and can be shaped to specifically fit most defects.
  • Plexur M provides porosity for bone growth after implantation and is fully resorbed by the body during the remodeling process.
  • Plexur M hardens at body temperature when applied within the body allowing surgeons to quickly move to the next step in the surgery.

The Plexur technology platform is a unique and patented combination of polymer and cortical bone fibers that supports a family of procedure-specific products targeted for use in a variety of orthopedic surgeries. Plexur technology-based products have been clinically shown to completely resorb into the body within six to twelve months and to be replaced by host bone. Plexur technology offers improved handling and an effective osteoconductive matrix with high levels of porosity that provides a broad surface area for new cell growth. Plexur is supported by more than 20 patents and patent applications and is the platform technology that supports Plexur P(TM) used in a variety of trauma and reconstructive surgeries and focused on foot and ankle procedures as well as Plexur M.

FacetLinx Fusion Technology

Facet joint disorders are among the most common of all the recurrent, disabling low back problems that have serious symptoms and disability. FacetLinx is a patent-pending spinal allograft product that treats mechanical and facet-driven back pain by fixating the facet joints or may augment standard instrumented and non-instrumented fusion, offering patients stability with minimum additional risks. FacetLinx offers a number of differentiating advantages over other facet fusion devices:

  • FacetLinx is quick, simple and has immediate efficacy, with reduced potential complications.
  • The FacetLinx system's less invasive design provides a cruciform shape that is more stable and will resist motion to thus aid in immediate back pain relief.
  • The FacetLinx system facilitates direct access to the cancellous bone on both sides of the facet joint to facilitate fusion.

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients through the development of innovative therapy-driven products that alleviate pain, promote regenerative and biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at

Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of November 11, 2009 and the Company does not intend to update this information.

SOURCE Osteotech, Inc.

SOURCE Osteotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Osteotech Reports Third Quarter 2009 Financial Results
2. Osteotechs MagniFuse(TM) Technology Used in First U.S. Surgery
3. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
4. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
5. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
6. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
7. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
8. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
9. New Campaign Highlights How Medical Products Distributors Streamline Healthcare
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
Post Your Comments:
(Date:11/24/2015)... Connecticut , November 24, 2015 ... of Acadiana has entered into a multi-year agreement ... imaging centers. This investment will provide the Breast Center ... --> Sectra (STO: SECT B) announces that ... agreement to deploy Breast Imaging PACS in its ...
(Date:11/24/2015)... , Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... its Board of Directors has declared a special 1 percent ... dividend is payable December 14, 2015, to shareholders of record ... form of additional shares of common stock. ... Board is a strong endorsement of our confidence in Ascendant,s ...
(Date:11/24/2015)... -- iRhythm Technologies, Inc. , a leading digital health care ... will participate in the 27th Annual Piper Jaffray Healthcare Conference at ... . Kevin King , Chief Executive Officer of ... 8:50am ET. --> --> ... . --> iRhythm is a privately held ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... 24, 2015 , ... It takes only three to five seconds to make ... the first impression be positive and reflects business values. If a client starts with ... want to return. They will also share their thoughts about a business with others, ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the ... study designed to yield insights into how to detect and treat pancreatic cancer (PC). ... cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present in the ...
(Date:11/24/2015)... ... 2015 , ... Sir Grout of Baltimore is proud to ... award recognizes good companies for excellence in service and a commitment to the ... surface restoration company earned this recognition after a thorough review by the acclaimed ...
Breaking Medicine News(10 mins):